EXO1 as a potential biomarker for prognosis, immune infiltration, and immunotherapy in pan-cancer analysis

被引:0
|
作者
Wang, Jikang [1 ,2 ,3 ]
Wang, Fubo [4 ]
Huang, Haoxuan [4 ]
机构
[1] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning 530021, Peoples R China
[2] Guangxi Med Univ, Collaborat Innovat Ctr Regenerat Med & Med BioReso, Nanning 530021, Peoples R China
[3] Guangxi Med Univ, Res Ctr Regenerat Med, Nanning 530021, Peoples R China
[4] Guangxi Med Univ, Ctr Genom & Personalized Med, Guangxi Collaborat Innovat Ctr Genom & Personalize, Guangxi Key Lab Genom & Personalized Med, Nanning 530021, Guangxi, Peoples R China
关键词
EXO1; Prognosis; Immune infiltration; Immunological biomarker; Immunotherapy; REPAIR; EXONUCLEASE-1;
D O I
10.1007/s10142-025-01586-1
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Human EXO1 is a 5' -> 3' exonuclease that plays a critical role in regulating cell cycle checkpoints, maintaining replication forks and participating in post-replication DNA repair pathways. Previous studies have highlighted the importance of EXO1 in cancers such as liver and breast cancer. However, there is a gap in the comprehensive analysis of EXO1 in a wide range of cancers, and its precise role in cancer patient prognosis and immune response remains unclear. This study aims to systematically investigate the potential associations between EXO1, immune infiltration and prognostic value in different cancer types and to gain a deeper understanding of its mechanisms of action.We conducted a comprehensive investigation into the overarching role of EXO1 across various cancers by utilizing multiple databases. Our analysis encompassed scrutinizing EXO1 expression and evaluating its correlation with clinical survival, immune checkpoints, Tumor Stemness Score, Prognostic Value, immunomodulators, genomic profiles, immunological characteristics, immunotherapy, and functional enrichment. EXO1 is expressed in various normal tissues and at significantly higher levels in most tumors compared to non-tumor tissues. High EXO1 expression is associated with poor prognosis in certain cancers. Genetic mutations and RNA modifications of EXO1 were also investigated, as well as its correlation with tumor immunity and genomic stability. We investigated the potential role of EXO1 in immunotherapy and identified differing drug responses based on EXO1 expression levels in Skin Cutaneous Melanoma (SKCM), which holds promise for personalized treatment. Furthermore, we analyzed EXO1-related genes and pathways, revealing its potential involvement in crucial biological processes such as DNA repair and cell cycle regulation. These findings provide a comprehensive understanding of the role of EXO1 in cancer initiation and progression, offering valuable insights for personalized cancer therapy and precision medicine. This study highlights the diverse functions of EXO1 in cancer, including its involvement in cancer initiation, prognosis, immune regulation, and response to immunotherapy. These findings provide valuable insights into the potential of EXO1 as a biomarker and therapeutic target, as well as its role in determining treatment response in cancer management. This information is crucial for guiding personalized cancer therapy and precision medicine.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Comprehensive pan-cancer analysis reveals SIRT5 is a predictive biomarker for prognosis and immunotherapy response
    Ji, Yacong
    Li, Chongyang
    Wan, Sicheng
    Zhang, Kui
    Liu, Yaling
    Shi, Shaomin
    FUNCTIONAL & INTEGRATIVE GENOMICS, 2024, 24 (02)
  • [42] Comprehensive pan-cancer analysis reveals SIRT5 is a predictive biomarker for prognosis and immunotherapy response
    Yacong Ji
    Chongyang Li
    Sicheng Wan
    Kui Zhang
    Yaling Liu
    Shaomin Shi
    Functional & Integrative Genomics, 2024, 24
  • [43] C1QTNF6 is a Prognostic Biomarker and Related to Immune Infiltration and Drug Sensitivity: A Pan-Cancer Analysis
    Liu, Wei
    Zhang, Jian
    Xie, Tao
    Huang, Xiaoting
    Wang, Baiyao
    Tian, Yunhong
    Yuan, Yawei
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [44] Pan-cancer analysis verifies COLGALT1 as a potential target for immunotherapy and survival prognosis
    Wang, Fengyan
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 49 - 49
  • [45] Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data
    Chong Shen
    Siyang Zhang
    Zhe Zhang
    Shaobo Yang
    Yu Zhang
    Yuda Lin
    Chong Fu
    Zhi Li
    Zhouliang Wu
    Zejin Wang
    Zhuolun Li
    Jian Guo
    Peng Li
    Hailong Hu
    Functional & Integrative Genomics, 2023, 23
  • [46] Pan-cancer analysis verifies COLGALT1 as a potential target for immunotherapy and survival prognosis
    Wang, Fengyan
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 49 - 49
  • [47] RelB is a potential molecular biomarker for immunotherapy in human pan-cancer
    Wu, Jintao
    Yu, Xinyu
    Zhu, Hongyu
    Chen, Peng
    Liu, Tongyan
    Yin, Rong
    Qiang, Yan
    Xu, Lin
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2023, 10
  • [48] Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis
    Ye, Yingquan
    Jiang, Haili
    Wu, Yue
    Wang, Gaoxiang
    Huang, Yi
    Sun, Weijie
    Zhang, Mei
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [49] Pan-cancer analysis reveals the relationship between RCSD1 immune infiltration and clinical prognosis in human tumors
    Qiao, Han
    Yin, Hong
    Feng, Yan
    Tang, Huaping
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [50] Multi-omics analysis identifies UBA family as potential pan-cancer biomarkers for tumor prognosis and immune microenvironment infiltration
    Wang, Haibin
    Liu, Xinli
    Huang, Hesen
    Tang, Meng
    Li, Jiwei
    Huang, Tingting
    Wang, Shengjie
    FRONTIERS IN IMMUNOLOGY, 2025, 16